Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. In a total of 49 patients, the MEP regimen had a 41% (9/22) overall response rate compared with 48% (13/27) for the MEP plus carboplatin (C-MEP) regimen (Chi-squared test, P=0.602). Among 38 CHOP-resistant patients, however, the overall response rate to C-MEP [42% (10/24)] was significantly superior compared with MEP [7% (1/14)] (P=0.023), and the overall survival to C-MEP was superior compared with MEP (P=0.088). Taken together, our results, although non-randomized, suggest that a combination of MEP with carboplatin is better than MEP alone in CHOP-resistant diffuse large B-cell lymphomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0145-2126(01)00114-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Blood
September 2023
Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Article Synopsis
- Diffuse large B-cell lymphoma (DLBCL) is a common type of non-Hodgkin lymphoma, with about 40% of patients not responding to standard chemotherapy treatments, leading to severe health issues.
- Researchers used a CRISPR-Cas9 library to discover that the E3 ubiquitin ligase KLHL6 plays a key role in making DLBCL cells resistant to chemotherapy by affecting the degradation of the NOTCH2 protein.
- Targeting DLBCL tumors that are resistant to chemotherapy with drugs like nirogacestat and ipatasertib could effectively promote tumor destruction by interfering with the oncogenic pathways linked to KLHL6 or NOTCH2 mutations.
[Effect of on the Drug Resistance of Diffuse Large B-Cell Lymphoma Cells by Regulating PD-1/PD-L1 Signaling Pathway].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
February 2023
Department of Hematology, Hebei General Hospital, Shijiazhuang 050055, Hebei Province, China.E-mail:
Objective: To explore the effect of microRNA-424-5p (miR-424-5p) on the drug resistance of diffuse large B-cell lymphoma (DLBCL) cells by regulating the programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) signaling pathway.
Methods: Human DLBCL cell line CRL2631 cells were induced to construct CRL2631-CHOP resistant cell line. RT-qPCR and Western blot were used to detect the expression levels of , PD-L1 mRNA and protein, and multidrug resistance gene-1 (MDR-1) protein in CRL2631 cells and CRL2631-CHOP cells, respectively.
CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance.
Pharmgenomics Pers Med
May 2021
Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Purpose: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma and of which the prognosis of activated B-cell-like (ABC) subtype is poor. Although R-CHOP significantly improves the survival of patients with DLBCL, 20% to 40% of patients were resistant to R-CHOP therapy. Thus, screening for candidate therapeutic targets for R-CHOP resistant patients is urgent.
View Article and Find Full Text PDFGM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting diffuse large B-cell lymphoma progression via influencing the macrophage polarization.
Cancer Cell Int
March 2021
Department of Hematology, First Affiliated Hospital of Zhejiang Chinese Medical University, 54 Youdian Road, 310006, Hangzhou, China.
Background: Diffuse large B-cell lymphoma (DLBCL) is a common type of the Non-Hodgkin lymphomas (NHLs) formed by the neoplastic transformation of mature B cells. As the first-line therapeutics, CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy and R-CHOP (Rituximab + CHOP), either using alone or in combination with GM-CSF, have achieved great efficacy in DLBCL patients. However, the underlying mechanisms are still largely unknown.
View Article and Find Full Text PDFPI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Theranostics
August 2021
Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Up to one-third of diffuse large B cell lymphoma (DLBCL) patients eventually develop resistance to R-CHOP regimen, while the remaining therapeutic options are limited. Thus, understanding the underlying mechanisms and developing therapeutic approaches are urgently needed. : We generated two germinal center B cell-like (GCB) and activated B cell-like (ABC) subtype R-CHO resistant DLBCL cell lines, of which the tumor-initiating capacity was evaluated by serial-transplantation and stemness-associated features including CD34 and CD133 expression, side population and ALDH1 activity were detected by flow cytometry or immunoblotting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!